Key points are not available for this paper at this time.
Although AVAGAST did not reach its primary objective, adding bevacizumab to chemotherapy was associated with significant increases in progression-free survival and overall response rate in the first-line treatment of advanced gastric cancer.
Ohtsu et al. (2011) studied this question.